Clinical Trial Update: A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Avastin (bevacizumab) plus capecitabine as maintenance therapy for HER2-negative metastatic breast cancer has completed and posted re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Avastin (bevacizumab)
• Xeloda (capecitabine)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2015-03-03